These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 12729034)

  • 1. Changes in monocyte phagocyting activity after multi-agent chemotherapy in non-small cell lung cancer.
    Mariotta S; Aquilini M; Ricci A; Papale M; Pabani R; Sposato B; Mannino F
    Eur Rev Med Pharmacol Sci; 2002; 6(4):67-73. PubMed ID: 12729034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radio- and chemotherapy variably affect the general immunocompetence of lung cancer patients.
    Vucković-Dekić L; Susnjar S; Stanojević-Bakić N; Radosavljević D
    Panminerva Med; 1999 Jun; 41(2):129-33. PubMed ID: 10479911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of cancer and chemotherapy on monocyte function.
    Lower EE; Baughman RP
    J Clin Lab Immunol; 1990 Mar; 31(3):121-5. PubMed ID: 1966996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
    Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
    Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
    Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A
    Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
    Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03.
    Teramukai S; Kitano T; Kishida Y; Kawahara M; Kubota K; Komuta K; Minato K; Mio T; Fujita Y; Yonei T; Nakano K; Tsuboi M; Shibata K; Furuse K; Fukushima M
    Eur J Cancer; 2009 Jul; 45(11):1950-8. PubMed ID: 19231158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer -- single institution retrospective analysis.
    Lee HW; Choi JH; Lim HY; Park JS; Kim HC; Kang S; Oh YT; Chun M; Sheen SS; Oh YJ; Park KJ; Hwang SC
    Neoplasma; 2006; 53(1):30-6. PubMed ID: 16416010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
    Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
    Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer.
    Pohl G; Krajnik G; Malayeri R; Müller RM; Klepetko W; Eckersberger F; Schäfer-Prokop C; Pokrajac B; Schmeikal S; Maier A; Ambrosch G; Woltsche M; Minar W; Pirker R
    Lung Cancer; 2006 Oct; 54(1):63-7. PubMed ID: 16926060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
    Imaizumi M;
    Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.
    Hensing TA; Schell MJ; Lee JH; Socinski MA
    Lung Cancer; 2005 Feb; 47(2):253-9. PubMed ID: 15639724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
    Wu C; Jiang J; Shi L; Xu N
    Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.
    Westeel V; Quoix E; Moro-Sibilot D; Mercier M; Breton JL; Debieuvre D; Richard P; Haller MA; Milleron B; Herman D; Level MC; Lebas FX; Puyraveau M; Depierre A;
    J Natl Cancer Inst; 2005 Apr; 97(7):499-506. PubMed ID: 15812075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
    Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.